Copy

Newsletter 5 - April 2015







Kick-Off COMBACTE-CARE

Well it finally happened; ND4BB Topic 5 came to fruition with the kick-off meeting for COMBACTE-CARE in Amsterdam. I was delighted with the attendance considering the long gestation period of this project. The commitment from all participants is testament to how seriously we all regard the issue of carbapenem resistance as a global public health issue. As part of the team originally drawing up the plans for the ND4BB programme, I am delighted that we now have a project addressing one of the key initial objectives. Read more..









KPC-3-producing K. pneumoniae detected in Albania

A successful collaboration between the COMBACTE LAB-Net team at the University of Antwerp, Belgium and the Microbiology Laboratory in the University Hospital “Shefqet Ndroqi”, Tirana, Albania resulted in the first detection of a KPC-3-producing Klebsiella pneumoniae in Albania. Read more..







Countdown to COMBACTE Investigators Meeting 2015

All roads lead to ECCMID 2015! Following a successful COMBACTE Investigators Meeting last year at ECCMID in Barcelona with more than a 100 participants from 19 different countries, we would like to invite you to this year’s COMBACTE Investigators Lunch Meeting in Copenhagen, Denmark. Register now! Read more..




 
Project Coordinator
Dr. Helen Steel
helen.m.steel@gsk.com

Academic Project Coordinator
Prof. Marc Bonten
M.J.M.Bonten@umcutrecht.nl
Academic Clinical Lead
Bruno Francois MD
bruno.francois@chu-limoges.fr

Deputy Project Co-ordinator
Seamus O'Brien
seamus.obrien@astrazeneca.com


Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!





Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

Email Marketing Powered by Mailchimp